Pfizer (NYSE:PFE) Price Target Raised to $36.00

Pfizer (NYSE:PFE) had its target price boosted by Guggenheim from $35.00 to $36.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price would suggest a potential upside of 34.47% from the stock’s previous close.

PFE has been the topic of several other reports. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.19.

Pfizer Price Performance

Pfizer stock opened at $26.77 on Tuesday. The stock has a market cap of $152.23 billion, a P/E ratio of 19.68 and a beta of 0.47. The company has a fifty day simple moving average of $26.71 and a 200-day simple moving average of $25.63. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.63 earnings per share. Equities analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently modified their holdings of PFE. Horizon Financial Services LLC lifted its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer in the third quarter valued at about $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 VALOR topline showed strong efficacy (reported ~73% in pre-specified analysis), giving the program clear commercial potential if approved. Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
• Positive Sentiment: Pfizer says it will seek regulatory review despite the trial miss, keeping a commercialization path alive and signaling management confidence in the data package. Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
• Positive Sentiment: Momentum and defensive income appeal: analysts and outlets note PFE’s stronger YTD performance and attractive dividend yield, factors that support investor interest amid broader market weakness. 5 High-Yield Stocks to Shield Your Portfolio From the Storm (PFE)
• Neutral Sentiment: The trial failed to meet its predefined primary endpoint because Lyme incidence was lower than expected; companies emphasize clinically meaningful efficacy on other statistical measures — outcome is data-positive but not conclusive. An experimental Lyme disease vaccine … findings aren’t conclusive (WSJ)
• Neutral Sentiment: Partner market reaction was severe (Valneva shares plunged), reflecting investor concern about statistical robustness and potential regulatory hurdles — a signal of market skepticism but not necessarily a direct hit to Pfizer’s balance sheet. Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
• Negative Sentiment: Missing the primary endpoint complicates the regulatory and commercial outlook — regulators could request additional analyses, labeling constraints, or more data, which would delay or reduce near-term revenue potential from the vaccine. Pfizer’s Lyme Vaccine Misses Mark in Study, Complicating Quest for Approval

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.